Stage T1 adenocarcinoma of the urinary bladder--complete response after transurethral resection and intravesical bacillus Calmette-Guerin.
OBJECTIVE
To report the results of treatment of adenocarcinoma of the urinary bladder with transurethral resection and intravesical bacillus Calmette-Guerin (BCG).


METHODS
Out of 183 patients in our department treated with BCG between 1992 and 1996, three patients had adenocarcinoma, stage T1.


RESULTS
All three patients had normal cystoscopy and negative cytology 53-82 months after the start of treatment.


CONCLUSIONS
BCG appears to be effective not only in the treatment of transitional cell carcinoma, but also in adenocarcinoma of the bladder.
Holmäng
S
S
Department of Urology, Sahlgrenska University Hospital, Göteborg, Sweden.
Aldenborg
F
F
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012074:Remission Induction; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine